Skip to main content
Premium Trial:

Request an Annual Quote

Althea Awarded NIH Toxicology Grant

NEW YORK, June 23 (GenomeWeb News) - Althea Technologies said today that it has received a Phase I Small Business Innovation Research grant from the National Institutes of Health, by way of the National Institute on Deafness and Other Communication Disorders, to develop a low cost mechanism for translating gene-expression-based research in toxicology into validated, high-throughput, expression screens for the assessment of a range of different toxicological and disease mechanistic endpoints.

 

The amount of the funding was not disclosed.

 

The approach will use Althea's eXpress Profiling technology, a high-throughput, highly-multiplexed, quantitative RT-PCR-based gene expression analysis technique, which was recently licensed to Beckman Coulter.

 

The new grant will focus on the development and validation of gene sets and predictive classifiers for specific and important toxicological endpoints. Althea's aim is to provide a roadmap for translating microarray-based discoveries into high throughput, low cost assays and validating their use in the drug discovery and development processes, the company said.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.